KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Current Deferred Revenue (2020 - 2025)

Historic Current Deferred Revenue for Pfizer (PFE) over the last 6 years, with Q3 2025 value amounting to $924.0 million.

  • Pfizer's Current Deferred Revenue fell 5425.74% to $924.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $924.0 million, marking a year-over-year decrease of 5425.74%. This contributed to the annual value of $1.5 billion for FY2024, which is 4403.7% down from last year.
  • As of Q3 2025, Pfizer's Current Deferred Revenue stood at $924.0 million, which was down 5425.74% from $1.1 billion recorded in Q2 2025.
  • Pfizer's 5-year Current Deferred Revenue high stood at $6.2 billion for Q4 2022, and its period low was $924.0 million during Q3 2025.
  • For the 5-year period, Pfizer's Current Deferred Revenue averaged around $2.5 billion, with its median value being $2.5 billion (2024).
  • As far as peak fluctuations go, Pfizer's Current Deferred Revenue skyrocketed by 17556.15% in 2021, and later crashed by 6619.35% in 2023.
  • Pfizer's Current Deferred Revenue (Quarter) stood at $3.1 billion in 2021, then fell by 17.84% to $2.5 billion in 2022, then rose by 7.14% to $2.7 billion in 2023, then crashed by 44.04% to $1.5 billion in 2024, then plummeted by 38.85% to $924.0 million in 2025.
  • Its Current Deferred Revenue was $924.0 million in Q3 2025, compared to $1.1 billion in Q2 2025 and $1.0 billion in Q1 2025.